P/F Ratio Calculator
Calculates the PaO₂/FiO₂ ratio — the standard oxygenation index used to classify the severity of acute respiratory distress syndrome (ARDS) by the Berlin definition. Essential for ICU triage, ventilator management, and prognostication in acute hypoxaemic respiratory failure.
Calculate P/F Ratio
Enter the PaO₂ from the arterial blood gas and the FiO₂ at the time the sample was drawn. Optionally enter PEEP level for full Berlin ARDS classification context and SpO₂ for an estimated S/F ratio. For the A-a gradient and alveolar oxygen calculation, see the A-a Gradient Calculator.
A low P/F ratio indicates impaired oxygenation but does not alone diagnose ARDS. The Berlin definition requires: (1) acute onset within one week, (2) bilateral opacities on chest imaging not fully explained by effusions, collapse, or nodules, (3) respiratory failure not fully explained by cardiac failure or fluid overload, and (4) minimum PEEP of 5 cmH₂O. All four criteria must be met.
Understanding the P/F Ratio
The PaO₂/FiO₂ ratio (commonly abbreviated P/F ratio) is the simplest and most widely used index of oxygenation efficiency. It expresses how effectively the lungs transfer oxygen from inspired gas to arterial blood, normalised for the amount of oxygen being delivered. A healthy pair of lungs on room air (PaO₂ ~100 mmHg, FiO₂ 0.21) produces a P/F ratio of approximately 475 — well above the normal threshold of 400–500.
As pulmonary gas exchange deteriorates — through V/Q mismatch, shunt, diffusion impairment, or alveolar flooding — the PaO₂ fails to rise proportionally with increasing FiO₂, and the P/F ratio falls. The ratio became the cornerstone of ARDS severity classification with the 2012 Berlin definition, replacing the older American-European Consensus Conference (AECC) criteria that used only a single cutoff of 200.
P/F Ratio Formula
P/F = PaO₂ ÷ FiO₂
PaO₂ in mmHg
FiO₂ as a decimal fraction (e.g. 0.40)
Normal P/F ratio: 400–500
ARDS threshold: ≤ 300 (with PEEP ≥ 5)
Worked Examples
Example 1: PaO₂ 95 on room air (FiO₂ 0.21)
P/F = 95 / 0.21 = 452 → Normal
Example 2: PaO₂ 68 on FiO₂ 40%
P/F = 68 / 0.40 = 170 → Moderate ARDS
Example 3: PaO₂ 55 on FiO₂ 80%
P/F = 55 / 0.80 = 69 → Severe ARDS
P/F ratio vs A-a gradient: Both assess oxygenation, but they answer different clinical questions. The A-a gradient determines whether hypoxaemia is caused by the lungs or by extrapulmonary factors (hypoventilation). The P/F ratio quantifies how severe the oxygenation impairment is and is preferred in the ICU setting because it remains clinically meaningful at any FiO₂, whereas the A-a gradient becomes unreliable at high FiO₂.
Berlin ARDS Classification
The 2012 Berlin definition stratifies ARDS into three mutually exclusive severity categories based on the P/F ratio, measured with a minimum PEEP of 5 cmH₂O. Each severity tier carries distinct prognostic and management implications.
| Severity | P/F Ratio | PEEP Requirement | Mortality | Key Considerations |
|---|---|---|---|---|
| No ARDS | > 300 | — | — | Normal oxygenation or non-ARDS cause of hypoxaemia |
| Mild | 200–300 | ≥ 5 cmH₂O | ~27% | May be managed with non-invasive ventilation in select patients |
| Moderate | 100–200 | ≥ 5 cmH₂O | ~32% | Lung-protective ventilation mandatory; consider prone positioning |
| Severe | < 100 | ≥ 5 cmH₂O | ~45% | Prone positioning; consider ECMO referral; neuromuscular blockade |
Complete Berlin Criteria — All Four Must Be Met
ARDS severity can change rapidly with ventilator adjustments. A patient who appears to have moderate ARDS (P/F 150) on PEEP 8 may reclassify as mild (P/F 250) after PEEP optimisation to 14. The Berlin definition recommends classifying severity at a standardised PEEP level, but in practice the P/F ratio is often recorded at the current ventilator settings. Always document the PEEP at the time of P/F measurement.
Management by ARDS Severity
The P/F ratio directly guides the intensity of respiratory support and adjunctive therapies. Evidence-based interventions are stratified by ARDS severity, with more aggressive strategies reserved for moderate-to-severe disease.
Lung-protective ventilation is the single most evidence-supported intervention in ARDS and should be applied to all intubated ARDS patients regardless of severity. The ARDSNet protocol (ARMA trial, 2000) demonstrated a 22% relative reduction in mortality using low tidal volumes.
- Tidal volume: 6 mL/kg predicted body weight (PBW), range 4–8 mL/kg PBW
- Plateau pressure: Target ≤ 30 cmH₂O
- Driving pressure: Target ≤ 15 cmH₂O (Pplat − PEEP)
- PEEP: Titrated using the ARDSNet low or high PEEP/FiO₂ tables, or by individualised recruitment/compliance assessment
- Permissive hypercapnia: Acceptable to maintain protective ventilation; pH target generally ≥ 7.20
PBW is calculated from height and sex, not actual body weight. Ventilating obese patients based on actual weight leads to injuriously high tidal volumes.
The PROSEVA trial (2013) demonstrated a significant mortality benefit for early prone positioning in moderate-to-severe ARDS (P/F < 150 on FiO₂ ≥ 0.60 and PEEP ≥ 5). Prone positioning improves V/Q matching by redistributing ventilation and perfusion more homogeneously, recruiting dependent lung regions, and improving chest wall mechanics.
- Indication: P/F < 150 within 12–24 hours of ARDS onset
- Duration: ≥ 16 consecutive hours per session (typically 16–20 hours)
- Continue until: P/F > 150 on FiO₂ ≤ 0.60 and PEEP ≤ 10 for ≥ 4 hours in the supine position
- Mortality reduction: Approximately 16% absolute reduction (PROSEVA) — one of the largest effects of any ICU intervention
Prone positioning is underutilised globally — compliance with guideline recommendations remains below 50% in many ICUs despite strong evidence. Early implementation is associated with better outcomes than delayed proning.
Neuromuscular blockade (NMB) with cisatracurium in early ARDS was initially shown to improve survival in the ACURASYS trial (2010). The subsequent ROSE trial (2019) did not replicate the mortality benefit with a lighter sedation strategy but confirmed safety. Current consensus favours short-term NMB (≤ 48 hours) for severe ARDS when lung-protective ventilation targets cannot be achieved due to patient-ventilator dyssynchrony or dangerously elevated driving pressures.
- Indication: P/F < 100–150 with difficulty achieving protective ventilation parameters despite adequate sedation
- Duration: Typically 24–48 hours; reassess daily
- Key consideration: Deep sedation is mandatory during paralysis; train-of-four monitoring recommended
NMB should not be used routinely in all ARDS patients. The primary role is in facilitating lung protection when spontaneous breathing efforts are causing injurious transpulmonary pressures or when prone positioning logistics require it.
Venovenous extracorporeal membrane oxygenation (VV-ECMO) should be considered for severe ARDS refractory to conventional maximal therapy (lung-protective ventilation, prone positioning, NMB, optimal PEEP). The EOLIA trial (2018) showed a trend toward mortality benefit, and a post-hoc Bayesian analysis suggests a high probability of benefit. The ELSO guidelines recommend referral when P/F < 80 for > 6 hours, P/F < 50 for > 3 hours, or pH < 7.25 with PaCO₂ ≥ 60 despite optimised ventilation.
- Consider referral: P/F < 80 despite prone + optimised PEEP + NMB
- Urgent referral: P/F < 50 for > 3 hours or uncompensated respiratory acidosis
- Contraindications: Irreversible underlying condition, prolonged mechanical ventilation (> 7–10 days), severe multi-organ failure, advanced age (relative — centre-dependent)
ECMO referral should occur early — do not wait until the patient is moribund. Contact the nearest ECMO centre while initiating other rescue therapies. Transport on ECMO is possible and is associated with better outcomes than late initiation.
The FACTT trial (2006) demonstrated that a conservative fluid strategy (targeting a lower CVP/PCWP) in ARDS patients improves oxygenation and shortens duration of mechanical ventilation without increasing organ failure, compared with a liberal fluid strategy. Once haemodynamically stable, ARDS patients should be managed with a conservative or restrictive fluid approach.
- Fluid balance: Target even or negative daily balance once resuscitation is complete
- Corticosteroids: Dexamethasone (DEXA-ARDS trial) or methylprednisolone may be considered in early moderate-to-severe ARDS — evidence is evolving; discuss within the treating team
- Inhaled vasodilators: Inhaled nitric oxide or epoprostenol may transiently improve oxygenation but have not demonstrated mortality benefit; consider as a temporising rescue measure
- Recruitment manoeuvres: Sustained inflations or incremental PEEP trials may recruit collapsed alveoli but carry risk of barotrauma; the ART trial (2017) found harm from aggressive recruitment — use cautiously and individualise
All ARDS → Lung-protective ventilation (6 mL/kg PBW, Pplat ≤ 30, driving pressure ≤ 15)
P/F < 150 → Early prone positioning (≥ 16 hours)
P/F < 100–120 → Consider neuromuscular blockade (48 hours), optimise PEEP
P/F < 80 refractory → Consider VV-ECMO referral
Common Pitfalls & Limitations
The P/F ratio is simple and widely used, but several common errors and limitations can lead to misclassification or inappropriate clinical decisions.
The P/F ratio is most reliable when the FiO₂ is precisely known — which is only guaranteed with a closed ventilator circuit or a fixed-performance device such as a Venturi mask. Nasal cannulae, simple face masks, and even non-rebreather masks deliver variable FiO₂ depending on flow rate, respiratory rate, tidal volume, and mouth breathing. The commonly cited “4% per litre” approximation for nasal cannula is imprecise and can lead to P/F miscalculations of 50–100 points.
High-flow nasal cannula (HFNC) delivers more reliable FiO₂ because it matches or exceeds the patient’s peak inspiratory flow demand, but even HFNC FiO₂ can be diluted if the flow rate is below the patient’s inspiratory flow. When using the P/F ratio for ARDS classification, aim to measure on a device with a known FiO₂. If using nasal cannula, document the estimated FiO₂ and recognise the inherent imprecision.
The P/F ratio is highly PEEP-dependent. The same patient may have a P/F of 120 on PEEP 5 and a P/F of 220 on PEEP 15 — one classifies as moderate ARDS, the other as mild. The Berlin criteria require a minimum PEEP of 5 cmH₂O to qualify as ARDS, but they do not mandate classification at a standardised PEEP level. This means severity can appear to change simply by adjusting PEEP.
In clinical practice, always document the PEEP at which the P/F ratio was measured. When discussing ARDS severity for prognostication or trial enrollment, some experts recommend assessing the P/F ratio at 24 hours on standardised settings, or using the P/F ratio at a PEEP of 5 cmH₂O as the “worst-case” reference. The key takeaway: a P/F ratio without a documented PEEP value is an incomplete data point.
A low P/F ratio indicates impaired oxygenation, but it is not synonymous with ARDS. Cardiogenic pulmonary oedema, acute eosinophilic pneumonia, diffuse alveolar haemorrhage, massive bilateral pneumonia, and pulmonary veno-occlusive disease can all produce P/F ratios below 200 without meeting the full Berlin criteria for ARDS. The Berlin definition explicitly requires that respiratory failure is not fully explained by cardiac failure or fluid overload.
Always confirm bilateral infiltrates on imaging, exclude cardiogenic oedema (echocardiography if needed), identify a known ARDS risk factor (sepsis, aspiration, pneumonia, trauma, transfusion, pancreatitis), and verify acute onset within one week. Applying ARDS-specific management (e.g., prone positioning) to cardiogenic pulmonary oedema may be ineffective or harmful.
Two patients may have identical P/F ratios but vastly different disease severity. A patient maintaining P/F 150 on FiO₂ 60% and PEEP 8 is in a very different clinical state from a patient achieving P/F 150 on FiO₂ 100% and PEEP 20. The P/F ratio alone does not capture the intensity of support required to achieve that oxygenation level.
The Oxygenation Index (OI = [FiO₂ × Mean Airway Pressure × 100] / PaO₂) incorporates mean airway pressure and provides a more complete picture of oxygenation efficiency relative to the intensity of ventilator support. An OI > 40 is often used as a threshold for ECMO consideration. Consider using the OI alongside the P/F ratio in severe ARDS to better capture the full picture of disease severity.
When arterial blood gas sampling is unavailable or impractical, the SpO₂/FiO₂ (S/F) ratio can serve as a non-invasive surrogate. Correlations suggest that S/F ≤ 315 corresponds roughly to P/F ≤ 300, and S/F ≤ 235 to P/F ≤ 200. The 2023 Global Definition of ARDS expanded the criteria to accept an S/F ratio ≤ 315 (when SpO₂ ≤ 97%) as an alternative to P/F ≤ 300 for ARDS diagnosis.
However, the S/F ratio has important limitations. SpO₂ accuracy decreases at saturations below 80%, in patients with dark skin pigmentation (which can overestimate SpO₂ by 2–4%), during poor perfusion states, and with dysfunctional haemoglobins (carboxyhaemoglobin, methaemoglobin). The flat upper portion of the oxygen-haemoglobin dissociation curve means that once SpO₂ reaches 97–100%, further increases in PaO₂ are not reflected, making the S/F ratio insensitive at high oxygenation levels. Always use ABG-derived P/F when available for formal ARDS classification.
Quick Reference Summary
(healthy lungs, room air)
(Berlin, PEEP ≥ 5)
Indication (PROSEVA)
Referral (EOLIA)
| P/F Ratio | Berlin Category | Mortality | Key Intervention |
|---|---|---|---|
| > 300 | No ARDS | — | Address underlying cause; monitor |
| 200–300 | Mild ARDS | ~27% | Lung-protective ventilation; consider NIV in select cases |
| 100–200 | Moderate ARDS | ~32% | Lung-protective vent + early prone if P/F < 150 |
| < 100 | Severe ARDS | ~45% | Prone + NMB ± ECMO referral |
The Golden Rule: Always document the PEEP and FiO₂ alongside the P/F ratio — a P/F number without ventilator context is an incomplete assessment. Severity can change with PEEP optimisation, and classification should reflect standardised conditions whenever possible.
Disclaimer & References
For Educational Purposes Only. This calculator and the accompanying clinical information are intended as educational tools for healthcare professionals. They do not replace clinical judgement. Results should be interpreted in the full clinical context. Lab reference ranges vary by institution — verify with your own laboratory. Drug dosages should be confirmed against current prescribing information.
References
- ARDS Definition Task Force; Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012;307(23):2526–2533. DOI: 10.1001/jama.2012.5669
- Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301–1308. DOI: 10.1056/NEJM200005043421801
- Guérin C, Reignier J, Richard JC, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368(23):2159–2168. DOI: 10.1056/NEJMoa1214103
- Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010;363(12):1107–1116. DOI: 10.1056/NEJMoa1005372
- Combes A, Hajage D, Capellier G, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. N Engl J Med. 2018;378(21):1965–1975. DOI: 10.1056/NEJMoa1800385
- National Heart, Lung, and Blood Institute ARDS Clinical Trials Network. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006;354(24):2564–2575. DOI: 10.1056/NEJMoa062200
- Moss M, Huang DT, Brower RG, et al. Early neuromuscular blockade in the acute respiratory distress syndrome (ROSE trial). N Engl J Med. 2019;380(21):1997–2008. DOI: 10.1056/NEJMoa1901686
- Matthay MA, Arabi Y, Arroliga AC, et al. A new global definition of acute respiratory distress syndrome. Am J Respir Crit Care Med. 2024;209(1):37–47. DOI: 10.1164/rccm.202303-0558WS
- Rice TW, Wheeler AP, Bernard GR, et al. Comparison of the SpO₂/FiO₂ ratio and the PaO₂/FiO₂ ratio in patients with acute lung injury or ARDS. Chest. 2007;132(2):410–417. DOI: 10.1378/chest.07-0617